Plantar exfoliation and desquamation during efalizumab therapy

Journal of the European Academy of Dermatology and Venereology

Volumn 22, Issue 5, 2008, Pages 633-634

  Adisen E ^a   Gurer M A ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

EFALIZUMAB; EMOLLIENT AGENT; STEROID;

ADULT; CASE REPORT; CLINICAL FEATURE; DESQUAMATION; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; ERYTHEMA; FEMALE; FOLLOW UP; FOOT SOLE; HUMAN; LETTER; PRIORITY JOURNAL; PSORIASIS VULGARIS; RECURRENT DISEASE; SCORING SYSTEM; SKIN EXFOLIATION; SKIN MANIFESTATION; SKIN TINGLING;

ADULT; ANTIBODIES, MONOCLONAL; DERMATITIS, EXFOLIATIVE; FEMALE; FOOT; HUMANS; PSORIASIS;

EID: 42149112160     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2007.02414.x     Document Type: Letter

References (9)

1. Sterry W, Stingl G, Langley RG et al.; CLEAR Multinational Study Group. CLEAR Multinational Study Group. Clinical Experience Acquired with Raptiva (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: Results from extended treatment in an international, Phase III, placebo-controlled trial. J Dtsch Dermatol Ges 2006; 4: 947-956.
2. Papp KA, Camisa C, Stone SP et al. Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: Review of clinical data. Part II. J Cutan Med Surg 2005; 9: 313-323.
3. Papp KA, Ho V, Langley R et al. Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis. J Cutan Med Surg 2006; 9: 26-32.
4. Wyatt AJ, Leonard GD, Sachs DL. Cutaneous reactions to chemotherapy and their management. Am J Clin Dermatol 2006; 7: 45-63.
5. Webster-Gandy JD, How C, Harrold K. Palmar-plantar erythrodysesthesia (PPE): A literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs 2007; 8; 238-246.
6. Wilkes GM, Doyle D. Palmar-plantar erythrodysesthesia. Clin J Oncol Nurs 2005; 9: 103-106.
7. Shiohara T, Mizukawa Y, Teraki Y. Pathophysiology of fix drug eruption: the role of skin-resident T cells. Curr Opin Allergy Clin Immunol 2002; 2: 317-323.
8. Shiohara T, Nicoloff BG, Sagawa Y et al. Fix drug eruption. Expression of epidermal keratinocyte intercellular adhesion molecule-1 (ICAM-1). Arc Dermatol 1989; 125: 1371-1376.
9. Mizukawa Y, Yamazaki Y, Teraki Y et al. Direct evidence for interferon-gamma production by effector-memory-type intraepidermal T cells residing at an effector site of immunopathology in fixed drug eruption. Am J Pathol 2002; 161: 1337-1347.